CRDF News and Press, Cardiff Oncology Inc.

2024-05-21 23:22:53 ET Summary Cardiff Oncology's Onvansertib is a first-in-class oral PLK1 inhibitor that targets difficult-to-treat cancers such as mCRC, mPDAC, SCLC, and TNBC. Onvansertib's promising early data suggest that it overcomes treatment resistance, improves response r...

SAN DIEGO, May 13, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will present at two upcoming investor conferences in M...

2024-05-09 12:15:23 ET Palm Beach, FL – May 9, 2024 – FN Media Group News Commentary – The incidence of pancreatic cancer is increasing globally, which is driving the growth of the market. As of 2023, the American Cancer Society predicts that 64,050 American...

2024-05-07 06:00:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Finding good investment opportunities in the constantly changing stock market is similar to uncovering hidden treasures. Certain cheap stocks to buy are particularly noteworthy because they can...

2024-05-03 10:00:37 ET More on Health Care Select Sector SPDR XLV: Pivotal Week Of Earnings For Healthcare Stocks XLV: Fundamentals Don't Support Overweighting Health Care XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance 19 out...

2024-05-03 08:36:49 ET More on pre-market losers & stocks. Safe & Green signs deal for design and production of eight units, currently in concept stage Seeking Alpha’s Quant Rating on AEON Biopharma, Inc. Historical earnings data for AEON Biopharma, In...

2024-05-03 01:30:09 ET Cardiff Oncology, Inc. (CRDF) Q1 2024 Results Earnings Conference Call May 2, 2024, 04:30 PM ET Company Participants Kiki Patel - Investor Relations, Gilmartin Group Mark Erlander - Chief Executive Officer Jamie Levine - Chief Financial Off...

2024-05-02 16:24:12 ET More on Cardiff Oncology Cardiff Oncology: Why The Bulls Are Winning Right Now (Rating Upgrade) Cardiff Oncology, Inc. (CRDF) Q4 2023 Earnings Call Transcript Cardiff Oncology, Inc. 2023 Q4 - Results - Earnings Call Presentation Seeking...

- In RAS-mutated mCRC, clinical data from ONSEMBLE trial, and preclinical data presented at AACR, demonstrated strong efficacy signal in bev naïve patients and support ongoing first-line RAS-mutated mCRC lead program - - In RAS wild-type mCRC, preclinical data presented at AACR dem...

Resideo Technologies Inc. (REZI) is expected to report $0.33 for Q1 2024 Schneider National Inc. (SNDR) is expected to report $0.13 for Q1 2024 Murphy Oil Corporation (MUR) is expected to report $0.82 for Q1 2024 Astronics Corp. - Class B (ATROB) is expected to report for Q1 2024 ...